1. Which of the following GLP-1 RAs is categorized as short-acting and primarily lowers post-prandial glucose levels?

2. MR is a 50-year-old obese female with uncontrolled T2D. Which of the following GLP-1 RAs would be preferred to initiate in this patient because it has demonstrated the largest amount of weight loss in clinical trials?

3. CC is a 60-year-old male with uncontrolled T2D. His primary care provider would like to start a GLP-1 RA but is concerned about the GI adverse effects. He would like to initiate the GLP-1 RA that has the best GI tolerability. Which agent would you recommend?

4. VO is a 52-year-old male with T2D and established ASCVD (post MI 2 years ago). He is taking metformin 1000 mg twice daily and his current A1C is 8% (goal < 7%). Which of the following GLP-1 RAs has an FDA indication to reduce the risk of major adverse cardiovascular events in adults with T2D and established CVD?

5. OT is a 64-year-old female with uncontrolled T2D. She takes metformin 1000 mg twice daily and her A1C today is 8.7%. Her primary care doctor would like to initiate therapy with a GLP-1 RA and asks you to counsel the patient on potential side effects she can anticipate and how to minimize those side effects. Which of the following counseling points would be most appropriate?

6. VC is a 66-year-old male with well controlled T2D on metformin 1000 mg twice daily. His most recent A1C was 6.9%. At his most recent visit with his primary care physician, he is diagnosed with chronic kidney disease based on two urinary albumin-to-creatinine ratios of 536 mg/g and 489 mg/g and an eGFR of 55 mL/min/1.73m2. Which of the following statements most accurately describes the guideline recommendations for the use of a GLP-1 RA in this patient?

7. MR is a 41-year-old female starting a GLP-1 RA. After consulting with her primary care provider, she has determined that she would like a product that is administered once weekly and is available in a single-use device with the needle already attached. Which of the following GLP-1 RAs meets the patient's desired criteria?

8. PN is a 54-year-old female with uncontrolled T2D. She takes metformin 1000 mg twice daily and pioglitazone 45 mg once daily. Her A1C is 8% (goal < 7%). Her provider wants to start a third diabetes medication. The patient wants to avoid injectable products and is fearful of hypoglycemia. Her doctor is considering oral semaglutide but is concerned about potential drug interactions. Her other medications include lisinopril, rosuvastatin, and levothyroxine. Which of the following statements most accurately describes the risk of a drug interaction with oral semaglutide?

9. QT is a 63-year-old male with T2D, for which he takes metformin 1000 mg twice daily and glipizide 10 mg twice daily. His A1C today is 7.5% (goal < 7%). He experiences hypoglycemia 1 to 2 times per week. His primary care provider is initiating a GLP-1 RA because of history of established ASCVD (myocardial infarction 6 months ago). Which of the following is the most reasonable plan for adjusting his background diabetes medications when initiating a GLP-1 RA?

10. SS is a 45-year-old male with well-controlled T2D on metformin 1000 mg by mouth twice daily and liraglutide 1.8 mg subcutaneously once daily. He is tolerating both medications well and is adherent. His insurance company has changed the preferred formulary GLP-1 RA from liraglutide (once daily) to injectable semaglutide (once weekly). Which of the following strategies would you recommend for this patient to switch from liraglutide to semaglutide?

Evaluation Questions

11. How confident are in your treatment choices for these patients presented in the post-test?

« Return to Activity